

1 **Skeletal effects of sleeve gastrectomy, by sex and menopausal status and in comparison**
2 **to Roux-en-Y gastric bypass surgery**

3
4 Karin C Wu^{1,2}, Po-Hung Wu³, Galateia Kazakia³, Sheena Patel⁴, Dennis M Black⁵, Thomas F
5 Lang³, Tiffany Y Kim^{1,2}, Nicole J King², Thomas J. Hoffman^{5,6}, Hanling Chang², Gaia Linfield¹,
6 Sarah Palilla⁷, Stanley J Rogers⁷, Jonathan T Carter⁷, Andrew M Posselt⁷, Anne L Schafer^{1,2,5}

- 7
8 1. Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
9 2. Endocrine Research Unit, San Francisco Veterans Affairs Health Care System, San
10 Francisco, CA, USA.
11 3. Department of Radiology, University of California San Francisco, San Francisco, CA, USA.
12 4. California Pacific Medical Center Research Institute, San Francisco, CA, USA.
13 5. Department of Epidemiology and Biostatistics, University of California San Francisco, San
14 Francisco, CA, USA.
15 6. Institute for Human Genetics, University of California San Francisco, San Francisco, CA,
16 USA.
17 7. Department of Surgery, University of California San Francisco, San Francisco, CA, USA.

18
19 **Corresponding Author & Reprint Requests:**

20 Karin C. Wu, MD
21 700 Owens St. RM 349, San Francisco, CA 94158 | Email: karin.wu@ucsf.edu

22
23 **Competing Interests:**

24 All authors have completed the ICMJE uniform disclosure form
25 at www.icmje.org/coi_disclosure.pdf and declare: Calcium citrate supplements were donated by
26 Bariatric Advantage for the submitted work; ALS has received investigator-initiated research

27 funding from Amgen and grant support from Bone Health Technologies; no other relationships
28 or activities that could appear to have influenced the submitted work.

29

30 **Funding:** This study was funded by the National Institute of Diabetes and Digestive and Kidney
31 Diseases (NIDDK, R01DK107629). Additional support came from a VA Career Development
32 Award (1IK2CX000549) to ALS, the NIDDK grant P30DK098722, the National Institute of
33 Arthritis and Musculoskeletal and Skin Diseases (NIAMS, P30AR075055), the National Center
34 for Advancing Translational Sciences (UL1TR001872), and the Northern California Institute for
35 Research and Education. KCW has received support from the Department of Veterans Affairs
36 and the NIDDK (T32DK007418). TYK is supported by a VA Career Development Award
37 (1IK2CX001984). Calcium citrate supplements were donated by Bariatric Advantage.

38 Manuscript content is solely the responsibility of the authors and does not necessarily represent
39 the official views of the National Institutes of Health.

40

41 **Data Availability:**

42 All data produced in the present study are available upon reasonable request to the authors.

43

44 **Abstract**

45 Context: Roux-en-Y gastric bypass (RYGB) has deleterious effects on bone mass,
46 microarchitecture, and strength. Data are lacking on the skeletal effects of sleeve gastrectomy
47 (SG), now the most commonly performed bariatric surgical procedure.

48 Objective: We examined changes in bone turnover, areal and volumetric bone mineral density
49 (aBMD, vBMD), and appendicular bone microarchitecture and estimated strength after SG. We
50 compared the results to those previously reported after RYGB, hypothesizing lesser effects after
51 SG than RYGB.

52 Design, Setting, Participants: Prospective observational cohort study of 54 adults with obesity
53 undergoing SG at an academic center.

54 Main Outcome Measure(s): Skeletal characterization with biochemical markers of bone
55 turnover, dual-energy X-ray absorptiometry (DXA), quantitative computed tomography (QCT),
56 and high-resolution peripheral QCT (HR-pQCT) was performed preoperatively and 6- and 12-
57 months postoperatively.

58 Results: Over 12 months, mean percentage weight loss was 28.8%. Bone turnover marker
59 levels increased, and total hip aBMD decreased -8.0% (95% CI -9.1%, -6.7%, $p < 0.01$). Spinal
60 aBMD and vBMD declines were larger in postmenopausal women than men. Tibial and radial
61 trabecular and cortical microstructure worsened, as did tibial estimated strength, particularly in
62 postmenopausal women. When compared to data from a RYGB cohort with identical design and
63 measurements, some SG biochemical, vBMD, and radial microstructural parameters were
64 smaller, while other changes were not.

65 Conclusions: Bone mass, microstructure, and strength decrease after SG. Some skeletal
66 parameters change less after SG than after RYGB, while for others, we find no evidence for
67 smaller effects after SG. Postmenopausal women may be at highest risk of skeletal
68 consequences after SG.

69

70 **Introduction**

71 One in 11 US adults (9.2%), and one in nine US women (11.2%), are living with severe or Class
72 3 obesity (body mass index [BMI] ≥ 40 kg/m²) (1). Obesity is linked to multiple comorbid
73 conditions and is associated with increased mortality (2, 3). Metabolic and bariatric surgery
74 (MBS) is a highly effective intervention for severe obesity, leading to marked and durable weight
75 loss, improvement in obesity-associated diseases, and decreased mortality (4, 5). However,
76 Roux-en-Y gastric bypass (RYGB), previously the most popular procedure and often considered
77 the gold-standard for metabolic benefit, has been shown to induce detrimental effects on
78 calcium homeostasis and skeletal health, with increases in bone turnover, decreases in bone
79 mineral density (BMD), weakened bone microarchitecture, and increased fracture incidence (6-
80 15).

81
82 Sleeve gastrectomy (SG) has emerged over the last decade and has overtaken RYGB as the
83 most commonly performed weight loss operation in the US and around the world (16, 17). SG
84 involves the removal of 60-80% of the stomach mass along the greater curvature, without the
85 alteration of the intestinal pathway that characterizes RYGB. Its rise in patient and surgeon
86 preference is largely due to the simpler surgical approach, lower peri- and postoperative
87 complication and mortality rates, and roughly clinically comparable long-term weight loss and
88 metabolic benefits (5, 18, 19). However, the impact of SG on skeletal health is still not well
89 characterized.

90
91 Published studies of skeletal effects of SG have generally examined areal BMD (aBMD) by
92 dual-energy X-ray absorptiometry (DXA), but DXA may be biased in the setting of marked body
93 composition changes and degenerative changes in the spine. Quantitative computed
94 tomography (QCT) and high-resolution peripheral QCT (HR-pQCT) are three-dimensional, non-

95 invasive methods for assessing volumetric BMD (vBMD) at the axial and appendicular skeleton
96 and for examining cortical and trabecular bone microarchitecture and estimated bone strength
97 (20, 21). Further, studies have inconsistently addressed the vitamin D deficiency that is so
98 common in severe obesity and with dietary restriction. Moreover, the relative skeletal effects of
99 SG by sex and menopausal status are uncertain. Because the majority of individuals who
100 undergo bariatric surgery are premenopausal women, studies of postoperative skeletal changes
101 after SG have largely focused on that group (22-25). However, postmenopausal women's
102 skeletons, already vulnerable due to age and sex steroid deficiency, may be particularly
103 affected, as we have shown after RYGB (13). If this is the case after SG, there may be clinical
104 implications for targeted screening and postoperative management.

105

106 The aim of this study was to examine the effects of SG on aBMD, vBMD, and appendicular
107 microarchitecture and estimated strength in a cohort of pre- and postmenopausal women and
108 men with severe obesity, in the setting of optimized 25-hydroxyvitamin D (25OHD) status and
109 recommended calcium intake. We also aimed to compare observed skeletal changes after SG
110 with changes reported in our previous cohort study of RYGB (13), which employed an identical
111 protocol and measurements. We hypothesized that bone mass, microstructure, and estimated
112 strength would decline, but to a lesser extent than RYGB, after SG.

113

114 **Materials and Methods**

115

116 Study design & population

117 We recruited women and men with severe obesity, aged 25 to 70 years, from an academic
118 bariatric surgery center (the University of California, San Francisco [UCSF]), as previously
119 described (26). Participants were eligible if they were scheduled for an upcoming SG procedure,
120 which was done laparoscopically and sometimes with robotic assist. Eligibility for bariatric

121 surgery at our institution was in accordance with the 1991 National Institutes of Health
122 consensus conference (BMI \geq 40 kg/m² or \geq 35 kg/m² with obesity-related comorbid conditions)
123 (27) and failure to lose weight with medical management. For this cohort study, we excluded
124 perimenopausal women (last menses > 3 months but < 4 years ago), and additional exclusion
125 criteria included a history of intestinal malabsorption or prior bariatric surgery, use of
126 medications known to impact bone and mineral metabolism (e.g. osteoporosis
127 pharmacotherapy, glucocorticoids, thiazolidinediones, aromatase inhibitors, androgen
128 deprivation therapy), diseases known to affect bone (e.g. primary hyperparathyroidism, Paget's
129 disease, hyperthyroidism defined by TSH < 0.1 mIU/L, clinically significant liver disease), illicit
130 drug use or alcohol use > 3 drinks/day, hypercalcemia (serum calcium > 10.2 mg/dL), chronic
131 kidney disease stage 4 or lower (eGFR < 30 mL/min/1.73m²), and weight > 200 kg (weight limit
132 of the DXA scanner).

133
134 Participants underwent study measurements preoperatively (no more than 3 months before the
135 SG) and at 6 months and 12 months postoperatively. However, the COVID19 pandemic
136 impeded our ability to adhere to the predefined timeline, particularly for the 12-month
137 postoperative visit. The mean \pm standard deviation (SD) for the 6-month postoperative timepoint
138 was 7.5 \pm 1.6 months and for the 12-month postoperative timepoint was 17.6 \pm 9.7 months.
139 After examining the distribution, we excluded data collected after 20 months postoperatively.

140
141 Protocol approval was obtained from the Institutional Review Board at the University of
142 California, San Francisco. Written informed consent was obtained from all participants. The
143 study was registered at the US National Institutes of Health (ClinicalTrials.gov, NCT02778490).

144
145 For comparison between SG and RYGB procedures, we used a previously completed (5 years
146 prior) pre-post observational cohort study of 48 women and men ages 25 to 70 years with

147 severe obesity undergoing RYGB at UCSF and the San Francisco Veterans Affairs Health Care
148 System (13, 28). The two cohort studies employed the identical approach/protocol, and
149 measurements and were made by the same research team, sequentially. The SG study was
150 designed to accommodate careful comparisons between these two cohorts.

151

152 Calcium and vitamin D supplementation

153 The research protocol included standardization of calcium intake and attention to vitamin D
154 status, following emerging clinical practice guidelines (29, 30). Vitamin D and chewable calcium
155 citrate supplements were provided upon enrollment (at least 2 weeks prior to the preoperative
156 measurements) and supplied throughout the study period. At enrollment, low 25OHD levels
157 were repleted to a target level ≥ 30 ng/mL, and vitamin D was supplemented with at least 3000
158 IU/day. Each participant's total daily calcium intake was brought to 1200 mg through
159 individualized calcium citrate dosing, based on estimation of intake from a validated screener
160 (31). Postoperatively, 25OHD levels and estimated dietary calcium intake were monitored, and
161 each participant's supplement doses were adjusted to maintain the vitamin D and calcium intake
162 goals.

163

164 Study measures

165 *DXA bone density and body composition*

166 Areal BMD (aBMD, g/cm²) at the lumbar spine (L1 to L4), proximal femur, and distal radius was
167 measured using DXA (Horizon A, Hologic) at each study time point. Whole-body DXA were also
168 performed for assessment of estimated total and regional body composition, including
169 percentage body fat (32). If the body dimensions exceeded the width of the scanning area, the
170 DXA manufacturer's reflection technique was utilized.

171

172 *QCT for spine bone density*

173 Spinal volumetric BMD ($vBMD$, g/cm^3) was assessed by QCT at the L3 and L4 vertebrae at 120
174 kVp, 200 mAs (General Electric's VCT64 scanner; General Electric, Milwaukee, WI, USA) at
175 each study time point and was analyzed according to methods previously described (Mindways
176 Software, Austin, TX, USA) (33, 34).

177

178 *HRpQCT for appendicular bone density, microarchitecture, and estimated strength*

179 Participants were imaged with a HRpQCT system (XtremeCT1, Scanco Medical, Brüttisellen,
180 Switzerland) at each study time point, using the manufacturer's standard in vivo protocol
181 (source potential 60 kVp, tube current 900 μ A, isotropic 82 μ m nominal resolution) (35-37). The
182 nondominant forearm and ankle were scanned. Fixed scan regions started at 9.5 mm proximal
183 to the mid-joint line for the ultradistal radius and 22.5 mm for the ultradistal tibia and extended
184 proximally for 9.02 mm (110 slices). Images were individually examined and rated for artifacts
185 as a result of soft tissue extension outside the field of view.

186

187 HR-pQCT images were analyzed using the manufacturer's standard clinical evaluation protocol
188 in Image Processing Language (IPL v5.08b, Scanco Medical) (38-40). Contours identifying the
189 periosteal perimeter of the bone were drawn semi-automatically using an edge-finding algorithm
190 (40) and manually examined and modified as necessary. A threshold-based process was used
191 to segment cortical and trabecular regions (40) and was manually checked for accurate
192 segmentation. Trabecular structure and cortical parameters were assessed using methods
193 previously described (41). Linear elastic micro-finite element analysis (μ FEA, Scanco FE
194 Software, Scanco Medical) was used to calculate biochemical properties (41-43).

195

196 *Other measures*

197 Weight and height were measured at each study time point, and BMI (kg/m^2) was calculated.

198 Waist circumference was measured at the level directly below the lowest rib, and hip

199 circumference at the maximum extension of the buttocks, viewed from the side.

200

201 Participants collected 24-hour urine specimens at each time point for measurement of urinary

202 calcium and creatinine. Serum samples were collected after an overnight fast at each study time

203 point. Basic chemistries including calcium, albumin, and phosphate, 25OHD, and parathyroid

204 hormone (PTH) were measured at a commercial laboratory (Quest Diagnostics, Secaucus, NJ,

205 USA). Additional serum samples were stored at -80°C until batch analyzed in a central

206 laboratory (MaineHealth Institute for Research, Scarborough, ME, USA). Serum C-terminal

207 cross-linked telopeptide (CTx; a marker of bone resorption), procollagen type 1 N-terminal

208 propeptide (P1NP; a marker of bone formation), and 1,25-dihydroxyvitamin D ($1,25[\text{OH}]_2\text{D}$) were

209 measured by chemiluminescence on an auto-analyzer (iSYS, Immunodiagnostic Systems,

210 Scottsdale, AZ). The inter- and intra-assay coefficients of variation (CV) were 6.0% and 3.2% for

211 CTx, 5.0% and 2.9% for P1NP, and 11.1% and 6.4% for $1,25(\text{OH})_2\text{D}$. Intestinal fractional

212 calcium absorption (FCA) was measured preoperatively and at 6 months postoperatively by a

213 gold-standard dual stable calcium isotope tracer method, as previously reported (26).

214

215 Statistical methods

216 Sample size calculations for this study were based on the mean changes, SD, and covariance

217 parameters identified in our previous pre-post RYGB cohort study (13), which had comparable

218 study population, study protocol, and measurements. We calculated that a sample of 50

219 participants would provide 80% power in 2-sided tests with $\alpha = 0.05$ to detect a percentage

220 reduction in femoral neck, total hip, and lumbar spine aBMD of 2.0%, 2.1%, and 1.8%,

221 respectively. These approximate the least significant change for DXA at our institution and the

222 change commonly considered clinically significant.

223
224 Baseline descriptive data were reported as means \pm SD, median (interquartile range [IQR]), or
225 proportions (N [%]). One-way ANOVA or Kruskal-Wallis were used as appropriate to determine
226 differences in baseline characteristics between sex and menopausal status (premenopausal
227 women, postmenopausal women, and men). Changes in weight and bone parameters over time
228 after SG were analyzed using mixed effect models with repeated measures with random subject
229 intercept and slope and fixed effect of time, with and without the interactions of sex and
230 menopausal status. Models were fitted with maximum likelihood estimation and were tested for
231 non-linear relationships with a quadratic time term. The percentage change in bone parameters
232 over 6 and 12 months and the confidence intervals for the predicted percentage changes were
233 estimated with model-based parametric bootstrap with 1000 resamples. Participants were
234 excluded from analysis if the 6-month postoperative percentage change for that bone parameter
235 was $> 3SD$ above or below the mean, suggesting a problem with the measurement of that
236 parameter.

237
238 Comparisons of the changes in bone imaging parameters, body composition, and laboratory
239 parameters between RYGB and SG were analyzed similarly using mixed effect models with
240 repeated measures with random subject intercept and slope and fixed effect of time*procedure.
241 These models were adjusted for age, sex, menopausal status, race, baseline weight, and
242 diabetes status, which were determined a priori in light of the relevant biology. Paired t-test or
243 Wilcoxon signed-rank tests were performed as appropriate to determine whether the changes in
244 bone turnover markers and FCA between preoperative and 6-month postoperative timepoints
245 differed between RYGB and SG cohorts. Linear models were then used to estimate the
246 adjusted associations. The 6-month postoperative data was used for comparison because it is
247 the study visit that is more closely matched in time since surgery between the two cohorts, given
248 the impact of the COVID19 pandemic on follow-up after SG. Further, the use of one

249 postoperative timepoint minimize the batch effect of serum analyses, and FCA was measured
250 only at the 6-month postoperative timepoint.

251
252 Statistical significance level was set at a two-sided p-value < 0.05, with corresponding 95%
253 confidence intervals. All data sets were managed using SAS software (version 9.4, SAS
254 Institute Inc., Cary, North Carolina, USA) and all statistical analyses were done using R (version
255 4.0.3) (44).

256

257 **Results**

258

259 Baseline SG participant characteristics

260 Fifty-four participants completed both pre- and postoperative skeletal imaging assessments.
261 Preoperatively, mean age \pm SD was 46.2 ± 11.1 years, weight was 126.0 ± 23.4 kg, and BMI
262 was 45.2 ± 7.5 kg/m² (Table 1). Of the 54 participants, 41 (76%) were women, with 15 (37%) of
263 those postmenopausal and 26 (63%) premenopausal. Mean 25OHD level at the preoperative
264 skeletal imaging assessments was 40.6 ± 13.7 ng/mL, which reflected preoperative repletion of
265 low levels that had been performed in accordance with clinical practice guidelines (29, 30).
266 Mean serum calcium, PTH, 1,25(OH)₂D, serum creatinine, and serum phosphate were within
267 their reference ranges. Median 24-hour urinary calcium level was 172 mg (IQR 80 to 270 mg).

268

269 Mean age for men was higher than for premenopausal women, but lower than for
270 postmenopausal women. Preoperative BMI was similar across sex and menopause groups.
271 However, men had higher preoperative weight, lower percentage body fat, higher waist
272 circumference, and higher waist-to-hip ratio. Vitamin D status, PTH, and other measures of
273 calcium homeostasis (FCA and 24-hour urinary calcium) did not differ by sex and menopausal
274 status. Men had higher bone turnover marker levels compared to premenopausal women.

275 Baseline aBMD by DXA at the spine and proximal femur did not differ by sex and menopause
276 status. Postmenopausal women and men had lower preoperative lumbar spine vBMD than
277 premenopausal women.

278

279 Weight loss after SG

280 Weight loss was dramatic after SG, with predicted 6-month percentage weight loss -21.8%
281 (95% CI -23.8%, -19.9%) of preoperative weight, and 12-month percentage weight loss -28.8%
282 (-31.3%, -26.0%) ($p < 0.01$ for both). Percentage weight loss did not differ by sex or
283 menopausal status.

284

285 Changes in biochemical markers of bone turnover after SG

286 Bone turnover markers increased markedly after SG. Serum CTX, a marker of bone resorption,
287 increased by a median +156% (IQR +89% to +279%) over 6 months, then at 12 months it was
288 still +87% above baseline (IQR +38% to +175%) ($p < 0.01$ for both). Serum P1NP, a marker of
289 bone formation, increased by a median +58% (IQR +33% to +100%) over 6 months, then at 12
290 months it was still +47% above baseline (IQR +11% to +82%) ($p < 0.01$ for both).

291

292 Changes in BMD after SG

293 Areal BMD at the proximal femur (DXA) decreased progressively after SG (Table 2), with
294 predicted 6- and 12-month declines at the femoral neck of -3.4% and -6.7%, respectively, and at
295 the total hip of -5.4% and -8.0%, respectively ($p < 0.01$ for both). There was a decline in lumbar
296 spine aBMD ($p = 0.03$) and a trend for decline in lumbar spine vBMD ($p = 0.07$). The decline in
297 lumbar spine aBMD by DXA was larger for postmenopausal women than for premenopausal
298 women or men (Figure 1a). The decline in lumbar spine vBMD by QCT was larger for women
299 than for men, with a decline of -5.8% in premenopausal women and -3.6% in postmenopausal
300 women vs. an increase of +8.2% in men over 12 months (Figure 1b).

301
302 Declines in appendicular vBMD after SG, measured by HR-pQCT, were smaller in magnitude
303 than declines in axial BMD. The decline in trabecular vBMD at the radius and tibia and total
304 vBMD at the tibia were statistically significant. The declines in total vBMD and cortical vBMD at
305 the tibia were largest in postmenopausal women (tibia total vBMD over 12 months: -5.8% in
306 postmenopausal women vs. -2.4% in premenopausal women vs. -1.1% in men, Figure 1c; tibia
307 cortical vBMD over 12 months: -3.3% in postmenopausal women vs. -0.5% in premenopausal
308 women vs. +0.4% in men, Figure 1d).

309
310 Changes in bone microarchitecture and estimated strength after SG
311 Within the trabecular compartment, changes in microarchitecture associated with diminished
312 skeletal strength were observed at the tibia and the radius (Table 3). There were decreases in
313 trabecular number and increases in trabecular separation and trabecular heterogeneity, as well
314 as in trabecular thickness. Increases in trabecular separation at the radius and trabecular area
315 at the tibia were larger for postmenopausal women (Figures 1e, 1f). Within the cortical
316 compartment, cortical pore size increased at both the radius and tibia (Table 3). There was also
317 a decrease in cortical thickness at the tibia, which was larger for postmenopausal women than
318 premenopausal women (Figure 1g).

319
320 Postoperative changes in estimated bone strength were apparent at the tibia, although not at
321 the radius (Table 3). Declines in failure load, stiffness, and apparent modulus were all worse in
322 postmenopausal women (Figure 1h, 1i, and 1j). The predicted decline in failure load over 12
323 months was -5.7% in postmenopausal women vs. -1.7% in premenopausal women vs. +0.3 in
324 men; the predicted decline in stiffness over 12 months was -5.5% in postmenopausal women
325 vs. -0.9% in premenopausal women vs. +1.3% in men; and the predicated decline in apparent

326 modulus over 12 months was -5.2% in postmenopausal women vs. -0.9% in premenopausal
327 women vs. +1.3% in men.

328

329 Comparison of participant characteristics and metabolic outcomes in the SG and RYGB cohort 330 studies

331 We used data from our previous pre-post observational cohort study of adults undergoing
332 RYGB (13), which employed an identical study design and measurements, to make careful
333 comparisons of the skeletal effects of SG and RYGB. At preoperative baseline, characteristics
334 were similar between cohorts. There were no differences in age, sex and menopausal
335 distribution, race, baseline weight and BMI, calciotropic hormone levels, or FCA. There were
336 more participants with diabetes in the RYGB cohort than in the SG cohort (40% vs. 19%, $p =$
337 0.03).

338

339 Postoperatively, percentage weight loss after SG approached, but was smaller than that after
340 RYGB (-21.9% after SG vs. -25.1% after RYGB over 6 months; -28.8% after SG vs. -30.8%
341 after RYGB over 12 months; $p < 0.01$ for procedure*time interaction in adjusted models).

342 Decrease in intestinal fractional calcium absorption over 6 months, reported previously not only
343 for RYGB (28) but also after SG (26), was worse after RYGB vs. SG (absolute mean decline of -
344 25.8% vs. -17.9%, $p < 0.01$ procedure*time interaction in adjusted models).

345

346 Changes in skeletal parameters in comparison with RYGB

347 Increases in bone turnover marker levels were larger after RYGB than after SG. The bone
348 resorption marker CTx increased by a median +276% (IQR +166% to +395%) over the 6
349 months after RYGB vs. by +156% (IQR +89% to +279%) after SG ($p < 0.01$ for difference
350 between procedures). The bone formation marker P1NP 6 months postoperatively increased by
351 a median +112% (IQR +71% to +153%) after RYGB vs. by +58% (IQR +33% to +100%) after

352 SG ($p < 0.01$ for difference between procedures). Differences between procedures persisted
353 even with adjustment for age, sex, menopausal status, and race.

354
355 By DXA, there was no evidence for differences between SG and RYGB in the extent of aBMD
356 decline at the proximal femur or lumbar spine. However, decline in lumbar spine vBMD by QCT
357 was larger after RYGB than SG (-7.8% after RYGB vs. -3.2% after SG over 12 months; Figure
358 2a). There was also a larger decline after RYGB than SG in total vBMD at the radius (Figure
359 2b). In terms of bone microarchitecture, at the radius, cortical thickness decreased more and
360 trabecular area increased more after RYGB (Figures 2c and 2d). In contrast, there were larger
361 changes after SG than RYGB in the trabecular compartment at the tibia, including larger
362 decreases in trabecular number and larger increases in trabecular separation and trabecular
363 heterogeneity (Figures 2e, 2f, 2g). There was no evidence for differences between surgical
364 procedures in estimated strength parameter change. All models were adjusted for age, sex,
365 menopausal status, race, preoperative weight, and diabetes status. To test whether the larger
366 weight loss after RYGB explained the larger change after RYGB for spinal vBMD or the larger
367 changes after RYGB at the radius for total vBMD, cortical thickness, or trabecular area, we
368 entered weight change into the multivariable model. For spinal vBMD change, adjustment for
369 weight change diminished the difference between surgical procedures, in that the point estimate
370 decreased by 31% and the p-value for procedure*time was no longer statistically significant. In
371 contrast, for radius total vBMD, cortical thickness, and trabecular area, point estimates changed
372 minimally and the differences between RYGB and SG maintained statistical significance.

373

374 **Discussion**

375

376 This prospective cohort study of SG and skeletal health is the largest to date to examine axial
377 and appendicular vBMD and appendicular bone microarchitecture and estimated strength. We

378 found detrimental effects of SG on bone mass, structure, and strength that worsened
379 progressively throughout the study duration (up to 20 months postoperatively). Our study is
380 unique in its examination of the relative skeletal effects of SG by sex and menopausal status.
381 Postmenopausal women are the population most burdened by lower bone mass and worse
382 bone microstructure, and in our data this group experienced the largest declines in many
383 skeletal health parameters after SG, including changes in BMD, bone microstructure, and
384 estimated strength.

385
386 At the axial skeleton, postoperative declines in BMD occurred early and were substantial,
387 particular at the proximal femur. The predicted 12-month percentage changes in aBMD were
388 comparable to the magnitude of bone loss expected over the 3-4 years of fastest bone loss
389 during the menopausal transition (45). Although the changes in lumbar spine vBMD by QCT
390 overall did not reach statistical significance, a decline was observed in women that was offset by
391 an increase in men. It is unclear why men had an increase in spine vBMD. One speculation is
392 that men tend to have more degenerative disc disease, which may be a cause of spurious
393 elevation not only for spine aBMD by DXA but also spine vBMD by QCT (46). In addition, in the
394 setting of higher preoperative weight and waist circumference in men, greater preoperative
395 abdominal soft tissue extension outside the CT scanner field of view could have result in more
396 beam hardening artifact (47). Beam hardening could result in underestimation of vBMD at
397 baseline and then an apparent increase in vBMD as weight is lost. Although QCT avoids the
398 biases of DXA that stem from 2-dimensional, single-projection data acquisition, QCT
399 assessments have nevertheless been shown to be influenced by obesity and weight loss (48).

400
401 There were also statistically significant declines in appendicular vBMD, albeit smaller in
402 magnitude than at the axial sites. At the radius and tibia, both the trabecular and cortical
403 compartments sustained detrimental effects, including decreases in trabecular number and

404 increases in trabecular separation and heterogeneity and cortical pore size. The fact that these
405 changes occurred at both the weight-bearing tibia and non-weight-bearing radius suggests at
406 least in part a systematic nature of the skeletal effects of SG. However, the deterioration in bone
407 density and microarchitecture was more pronounced at the weight-bearing skeleton. At the tibia,
408 there were additional increases in trabecular area with decreases in cortical thickness at the
409 tibia, consistent with endocortical resorption, and the impairment in bone density and
410 microarchitecture translated into declines in estimated strength. The specificity for the tibia
411 suggests that the mechanical unloading of weight loss may contribute in part to overall skeletal
412 changes.

413
414 Postmenopausal women had worse declines than premenopausal women and men in some
415 bone mass and microarchitectural parameters and in all estimated strength parameters at the
416 tibia. This may reflect a heightened sensitivity of the already vulnerable postmenopausal
417 skeleton—already vulnerable from age and sex hormone deficiency—to SG-induced bone
418 metabolism abnormalities. The findings corroborate our previously reported finding that
419 postmenopausal women were particularly impacted by skeletal effects of RYGB (13). If
420 postmenopausal women are at highest risk for bariatric surgery-induced skeletal complications,
421 there are implications for clinical care; it may be appropriate to target postmenopausal women
422 with skeletal health screening, monitoring, and therapeutic interventions as they undergo RYGB
423 or SG. Interventions have been studied: For example, a randomized controlled trial of a
424 multipronged program of exercise, calcium, vitamin D, and protein supplementation was able to
425 attenuate postoperative bone loss compared to no intervention in premenopausal women and
426 men undergoing RYGB or SG (49). Ongoing clinical trials are now examining the safety and
427 efficacy of osteoporosis pharmacologic interventions to reduce bariatric surgery-associated
428 bone loss.

429

430 We were uniquely positioned to compare the skeletal effects of SG to those of RYGB, as we
431 previously conducted a pre-post RYGB cohort study with identical study design and protocol
432 (13). The two cohorts were remarkably similar in baseline characteristics, but we nevertheless
433 adjusted our models for key baseline parameters. Increases in bone turnover marker levels
434 were larger after RYGB than after SG. For DXA-assessed aBMD change, we did not detect
435 differences between the surgical procedures. This finding is consistent with a recent meta-
436 analysis of 14 studies on the effects of RYGB vs. SG on bone mineral density, which did not
437 identify significant differences in aBMD change at the total hip, femoral neck, and lumbar spine
438 (50). No prior studies have examined QCT or HRpQCT BMD, bone microstructure, or estimated
439 strength between procedures. By QCT, we found that spinal vBMD decline was worse after
440 RYGB than after SG. By HRpQCT, at the radius we demonstrated worse total vBMD decline
441 and worse cortical thickness decline (with associated increase in trabecular area) after RYGB
442 than after SG. Conversely, at the tibia, SG seemed to lead to worse microarchitectural changes
443 in the trabecular compartment than RYGB. There were no differences in the decline in
444 estimated bone strength between the two surgical procedures.

445
446 A number of potential factors may explain differential skeletal outcomes after the two surgical
447 procedures. One such factor is extent of weight loss, which was not quite as large after SG as
448 after RYGB. Our analyses suggest that the larger decline in spinal vBMD after RYGB compared
449 to SG was explained by the greater weight loss experienced by the RYGB cohort. However, the
450 larger declines at the radius for total vBMD and cortical thickness (with associated increase in
451 trabecular area) after RYGB were not explained by greater weight loss after RYGB. Participants
452 in both our cohorts underwent measurement of intestinal fractional calcium absorption, reported
453 previously (26, 28), using a gold-standard dual stable isotope method. Decline in intestinal
454 calcium absorption after SG, while marked, was less severe than after RYGB. This could
455 contribute to the larger bone turnover marker increases and larger changes in select parameters

456 at the radius after RYGB compared to SG. There are fewer potential explanations for our finding
457 that SG seemed to lead to worse trabecular microarchitectural changes than RYGB at the tibia.
458 In a published study comparing RYGB and SG over 12 months, there was an increase in bone
459 marrow adiposity after SG but not RYGB (51), and one could speculate that an increase in
460 marrow adiposity could lead to worsening trabecular microarchitecture.

461
462 Major strengths of our study include its prospective, longitudinal design, and the very
463 comprehensive measurement of skeletal health using DXA, QCT, and HRpQCT as well as
464 biochemical markers of bone turnover. Our cohort is unique as it included nearly 30% of
465 postmenopausal women and nearly 25% of men, who are often excluded from or play a small
466 role in SG research, because the majority of patients undergoing bariatric surgery are
467 premenopausal women. Indeed, in a prior worldwide study from 2018, 73.7% of patients
468 undergoing bariatric surgery were women with a median (IQR) age of 42 years (33-51) (17). Our
469 study protocol included the careful, individualized supplementation of calcium and vitamin D in
470 order to study the skeletal effects of SG in the setting of adherence to current standardized
471 professional recommendations (52) .

472
473 A limitation of our study is its modest duration; we did not determine the longer-term skeletal
474 effects in our cohorts. The COVID19 pandemic impeded our ability to adhere to the protocol's
475 predefined timeline for study visits. However, we completed follow-up when we were able to do
476 so, in fact exceeding our planned sample size, and we revised our statistical analysis plan to
477 employ robust mixed-effect models taking into account the time to follow-up. Although we were
478 able to make comparisons between SG and RYGB procedures using data from pre-post cohort
479 studies that employed the same protocol and measurements and drew from the same bariatric
480 surgery center, this was not a randomized controlled trial, nor was there a nonsurgical control
481 group for full comparison. While our study is the largest to date to examine axial and

482 appendicular vBMD and appendicular bone microarchitecture and strength, the sizes of the sex
483 and menopause subgroups were modest. Future studies should enroll larger groups of
484 postmenopausal women and men.

485
486 In conclusion, SG negatively impacts axial and appendicular BMD and appendicular bone
487 microarchitecture and estimated strength. Increases in bone turnover marker levels and
488 declines in some measures of bone mass and microarchitecture, while clinically and statistically
489 significant after SG, are less severe after SG than after RYGB. For many other measures of
490 bone mass, microarchitecture, and estimated strength, our data do not provide evidence for
491 differences between the surgical procedures, or our data even suggest larger changes after SG.
492 Postmenopausal women may be at highest risk of skeletal consequences after SG and RYGB,
493 and thus targeted screening, monitoring, and interventions may be particularly appropriate for
494 postmenopausal women undergoing SG. Further research should evaluate approaches to the
495 prevention of long-term skeletal consequences of these otherwise beneficial metabolic
496 procedures.

497

498

499 **Acknowledgements**

500 The authors thank Elliazar Enriquez, LVN for his facilitation of study recruitment; Aldric Chau for
501 his work on QCT scan analysis; and Dolores Shoback, MD for her expert advice.

502

503 References

- 504 1. Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of Obesity and Severe Obesity
505 Among Adults: United States, 2017-2018. *NCHS Data Brief*. 2020(360):1-8.
- 506 2. Global BMIMC, Di Angelantonio E, Bhupathiraju Sh N, Wormser D, Gao P, Kaptoge S,
507 et al. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239
508 prospective studies in four continents. *Lancet*. 2016;388(10046):776-86.
- 509 3. Abdelaal M, le Roux CW, Docherty NG. Morbidity and mortality associated with obesity.
510 *Ann Transl Med*. 2017;5(7):161.
- 511 4. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrenbach K, et al. Bariatric
512 surgery: a systematic review and meta-analysis. *JAMA : the journal of the American Medical*
513 *Association*. 2004;292(14):1724-37.
- 514 5. Chang SH, Stoll CR, Song J, Varela JE, Eagon CJ, Colditz GA. The effectiveness and
515 risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012. *JAMA*
516 *surgery*. 2014;149(3):275-87.
- 517 6. Nakamura KM, Haglund EG, Clowes JA, Achenbach SJ, Atkinson EJ, Melton LJ, 3rd, et
518 al. Fracture risk following bariatric surgery: a population-based study. *Osteoporosis international*
519 *: a journal established as result of cooperation between the European Foundation for*
520 *Osteoporosis and the National Osteoporosis Foundation of the USA*. 2014;25(1):151-8.
- 521 7. Stein EM, Silverberg SJ. Bone loss after bariatric surgery: causes, consequences, and
522 management. *The lancet Diabetes & endocrinology*. 2014;2(2):165-74.
- 523 8. Rousseau C, Jean S, Gamache P, Lebel S, Mac-Way F, Biertho L, et al. Change in
524 fracture risk and fracture pattern after bariatric surgery: nested case-control study. *BMJ*.
525 2016;354:i3794.
- 526 9. Yu EW, Lee MP, Landon JE, Lindeman KG, Kim SC. Fracture Risk After Bariatric
527 Surgery: Roux-en-Y Gastric Bypass Versus Adjustable Gastric Banding. *J Bone Miner Res*.
528 2017;32(6):1229-36.
- 529 10. Axelsson KF, Werling M, Eliasson B, Szabo E, Näslund I, Wedel H, et al. Fracture Risk
530 After Gastric Bypass Surgery: A Retrospective Cohort Study. *Journal of bone and mineral*
531 *research : the official journal of the American Society for Bone and Mineral Research*.
532 2018;33(12):2122-31.
- 533 11. Gagnon C, Schafer AL. Bone Health After Bariatric Surgery. *JBMR plus*. 2018;2(3):121-
534 33.
- 535 12. Lindeman KG, Greenblatt LB, Rourke C, Bouxsein ML, Finkelstein JS, Yu EW.
536 Longitudinal 5-Year Evaluation of Bone Density and Microarchitecture After Roux-en-Y Gastric
537 Bypass Surgery. *The Journal of clinical endocrinology and metabolism*. 2018;103(11):4104-12.
- 538 13. Schafer AL, Kazakia GJ, Vittinghoff E, Stewart L, Rogers SJ, Kim TY, et al. Effects of
539 Gastric Bypass Surgery on Bone Mass and Microarchitecture Occur Early and Particularly
540 Impact Postmenopausal Women. *Journal of bone and mineral research : the official journal of*
541 *the American Society for Bone and Mineral Research*. 2018;33(6):975-86.
- 542 14. Zhang Q, Chen Y, Li J, Chen D, Cheng Z, Xu S, et al. A meta-analysis of the effects of
543 bariatric surgery on fracture risk. *Obes Rev*. 2018;19(5):728-36.
- 544 15. Paccou J, Martignone N, Lespessailles E, Babykina E, Pattou F, Cortet B, et al. Gastric
545 Bypass But Not Sleeve Gastrectomy Increases Risk of Major Osteoporotic Fracture: French
546 Population-Based Cohort Study. *J Bone Miner Res*. 2020;35(8):1415-23.
- 547 16. Ponce J, Nguyen NT, Hutter M, Sudan R, Morton JM. American Society for Metabolic
548 and Bariatric Surgery estimation of bariatric surgery procedures in the United States, 2011-
549 2014. *Surg Obes Relat Dis*. 2015;11(6):1199-200.
- 550 17. Welbourn R, Hollyman M, Kinsman R, Dixon J, Liem R, Ottosson J, et al. Bariatric
551 Surgery Worldwide: Baseline Demographic Description and One-Year Outcomes from the
552 Fourth IFSO Global Registry Report 2018. *Obes Surg*. 2019;29(3):782-95.

- 553 18. Howard R, Chao GF, Yang J, Thumma J, Chhabra K, Arterburn DE, et al. Comparative
554 Safety of Sleeve Gastrectomy and Gastric Bypass Up to 5 Years After Surgery in Patients With
555 Severe Obesity. *JAMA Surg.* 2021.
- 556 19. Biter LU, Hart JW, Noordman BJ, Smulders JF, Nienhuijs S, Dunkelgrun M, et al. Long-
557 term effect of sleeve gastrectomy vs Roux-en-Y gastric bypass in people living with severe
558 obesity: a phase III multicentre randomised controlled trial (SleeveBypass). *Lancet Reg Health*
559 *Eur.* 2024;38:100836.
- 560 20. MacNeil JA, Boyd SK. Accuracy of high-resolution peripheral quantitative computed
561 tomography for measurement of bone quality. *Med Eng Phys.* 2007;29(10):1096-105.
- 562 21. Burghardt AJ, Kazakia GJ, Majumdar S. A local adaptive threshold strategy for high
563 resolution peripheral quantitative computed tomography of trabecular bone. *Ann Biomed Eng.*
564 2007;35(10):1678-86.
- 565 22. Carrasco F, Basfi-Fer K, Rojas P, Valencia A, Csendes A, Codoceo J, et al. Changes in
566 bone mineral density after sleeve gastrectomy or gastric bypass: relationships with variations in
567 vitamin D, ghrelin, and adiponectin levels. *Obes Surg.* 2014;24(6):877-84.
- 568 23. Carrasco F, Basfi-Fer K, Rojas P, Csendes A, Papapietro K, Codoceo J, et al. Calcium
569 absorption may be affected after either sleeve gastrectomy or Roux-en-Y gastric bypass in
570 premenopausal women: a 2-y prospective study. *Am J Clin Nutr.* 2018;108(1):24-32.
- 571 24. Muschitz C, Kocijan R, Marterer C, Nia AR, Muschitz GK, Resch H, et al. Sclerostin
572 levels and changes in bone metabolism after bariatric surgery. *J Clin Endocrinol Metab.*
573 2015;100(3):891-901.
- 574 25. Hsin MC, Huang CK, Tai CM, Yeh LR, Kuo HC, Garg A. A case-matched study of the
575 differences in bone mineral density 1 year after 3 different bariatric procedures. *Surg Obes*
576 *Relat Dis.* 2015;11(1):181-5.
- 577 26. Wu KC, Cao S, Weaver CM, King NJ, Patel S, Kim TY, et al. Intestinal Calcium
578 Absorption Decreases After Laparoscopic Sleeve Gastrectomy Despite Optimization of Vitamin
579 D Status. *J Clin Endocrinol Metab.* 2023;108(2):351-60.
- 580 27. NIH conference. Gastrointestinal surgery for severe obesity. Consensus Development
581 Conference Panel. *Annals of internal medicine.* 1991;115(12):956-61.
- 582 28. Schafer AL, Weaver CM, Black DM, Wheeler AL, Chang H, Szefc GV, et al. Intestinal
583 Calcium Absorption Decreases Dramatically After Gastric Bypass Surgery Despite Optimization
584 of Vitamin D Status. *Journal of bone and mineral research : the official journal of the American*
585 *Society for Bone and Mineral Research.* 2015;30(8):1377-85.
- 586 29. Mechanick JI, Youdim A, Jones DB, Garvey WT, Hurley DL, McMahon MM, et al.
587 Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support
588 of the bariatric surgery patient--2013 update: cosponsored by American Association of Clinical
589 Endocrinologists, the Obesity Society, and American Society for Metabolic & Bariatric Surgery.
590 *Endocrine practice : official journal of the American College of Endocrinology and the American*
591 *Association of Clinical Endocrinologists.* 2013;19(2):337-72.
- 592 30. Parrott J, Frank L, Rabena R, Craggs-Dino L, Isom KA, Greiman L. American Society for
593 Metabolic and Bariatric Surgery Integrated Health Nutritional Guidelines for the Surgical Weight
594 Loss Patient 2016 Update: Micronutrients. *Surgery for obesity and related diseases : official*
595 *journal of the American Society for Bariatric Surgery.* 2017;13(5):727-41.
- 596 31. Hacker-Thompson A, Robertson TP, Sellmeyer DE. Validation of two food frequency
597 questionnaires for dietary calcium assessment. *Journal of the American Dietetic Association.*
598 2009;109(7):1237-40.
- 599 32. Scherzer R, Shen W, Bacchetti P, Kotler D, Lewis CE, Shlipak MG, et al. Comparison of
600 dual-energy X-ray absorptiometry and magnetic resonance imaging-measured adipose tissue
601 depots in HIV-infected and control subjects. *Am J Clin Nutr.* 2008;88(4):1088-96.
- 602 33. Lang TF, Li J, Harris ST, Genant HK. Assessment of vertebral bone mineral density
603 using volumetric quantitative CT. *J Comput Assist Tomogr.* 1999;23(1):130-7.

- 604 34. Khoo BC, Brown K, Cann C, Zhu K, Henzell S, Low V, et al. Comparison of QCT-derived
605 and DXA-derived areal bone mineral density and T scores. *Osteoporos Int.* 2009;20(9):1539-45.
- 606 35. Boutroy S, Van Rietbergen B, Sornay-Rendu E, Munoz F, Bouxsein ML, Delmas PD.
607 Finite element analysis based on in vivo HR-pQCT images of the distal radius is associated with
608 wrist fracture in postmenopausal women. *J Bone Miner Res.* 2008;23(3):392-9.
- 609 36. Melton LJ, 3rd, Riggs BL, van Lenthe GH, Achenbach SJ, Muller R, Bouxsein ML, et al.
610 Contribution of in vivo structural measurements and load/strength ratios to the determination of
611 forearm fracture risk in postmenopausal women. *J Bone Miner Res.* 2007;22(9):1442-8.
- 612 37. Sornay-Rendu E, Boutroy S, Munoz F, Delmas PD. Alterations of cortical and trabecular
613 architecture are associated with fractures in postmenopausal women, partially independent of
614 decreased BMD measured by DXA: the OFELY study. *J Bone Miner Res.* 2007;22(3):425-33.
- 615 38. Boutroy S, Bouxsein ML, Munoz F, Delmas PD. In vivo assessment of trabecular bone
616 microarchitecture by high-resolution peripheral quantitative computed tomography. *J Clin
617 Endocrinol Metab.* 2005;90(12):6508-15.
- 618 39. Khosla S, Riggs BL, Atkinson EJ, Oberg AL, McDaniel LJ, Holets M, et al. Effects of sex
619 and age on bone microstructure at the ultradistal radius: a population-based noninvasive in vivo
620 assessment. *J Bone Miner Res.* 2006;21(1):124-31.
- 621 40. Laib A, Hauselmann HJ, Ruegsegger P. In vivo high resolution 3D-QCT of the human
622 forearm. *Technol Health Care.* 1998;6(5-6):329-37.
- 623 41. Kazakia GJ, Tjong W, Nirody JA, Burghardt AJ, Carballido-Gamio J, Patsch JM, et al.
624 The influence of disuse on bone microstructure and mechanics assessed by HR-pQCT. *Bone.*
625 2014;63:132-40.
- 626 42. Macneil JA, Boyd SK. Bone strength at the distal radius can be estimated from high-
627 resolution peripheral quantitative computed tomography and the finite element method. *Bone.*
628 2008;42(6):1203-13.
- 629 43. Mueller TL, Christen D, Sandercott S, Boyd SK, van Rietbergen B, Eckstein F, et al.
630 Computational finite element bone mechanics accurately predicts mechanical competence in
631 the human radius of an elderly population. *Bone.* 2011;48(6):1232-8.
- 632 44. Team RC. R: A language environment for statistical computing. 2021 [Available from:
633 <https://www.R-project.org/>].
- 634 45. Greendale GA, Sowers M, Han W, Huang MH, Finkelstein JS, Crandall CJ, et al. Bone
635 mineral density loss in relation to the final menstrual period in a multiethnic cohort: results from
636 the Study of Women's Health Across the Nation (SWAN). *J Bone Miner Res.* 2012;27(1):111-8.
- 637 46. Okano I, Salzmann SN, Jones C, Ortiz Miller C, Shirahata T, Rentenberger C, et al. The
638 impact of degenerative disc disease on regional volumetric bone mineral density (vBMD)
639 measured by quantitative computed tomography. *Spine J.* 2020;20(2):181-90.
- 640 47. Van Gompel G, Van Slambrouck K, Defrise M, Batenburg KJ, de Mey J, Sijbers J, et al.
641 Iterative correction of beam hardening artifacts in CT. *Med Phys.* 2011;38 Suppl 1:S36.
- 642 48. Yu EW, Thomas BJ, Brown JK, Finkelstein JS. Simulated increases in body fat and
643 errors in bone mineral density measurements by DXA and QCT. *J Bone Miner Res.*
644 2012;27(1):119-24.
- 645 49. Muschitz C, Kocijan R, Haschka J, Zendeli A, Pirker T, Geiger C, et al. The Impact of
646 Vitamin D, Calcium, Protein Supplementation, and Physical Exercise on Bone Metabolism After
647 Bariatric Surgery: The BABS Study. *J Bone Miner Res.* 2016;31(3):672-82.
- 648 50. Salman MA, Aradaib M, Salman A, Elewa A, Tourky M, Shaaban HE. Effects of Gastric
649 Bypass and Sleeve Gastrectomy on Bone Mineral Density and Bone Turnover Markers: A
650 Systematic Review and Meta-Analysis. *World J Surg.* 2022;46(4):865-75.
- 651 51. Bredella MA, Greenblatt LB, Eajazi A, Torriani M, Yu EW. Effects of Roux-en-Y gastric
652 bypass and sleeve gastrectomy on bone mineral density and marrow adipose tissue. *Bone.*
653 2017;95:85-90.

654 52. Mechanick JI, Apovian C, Brethauer S, Garvey WT, Joffe AM, Kim J, et al. Clinical
655 practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients
656 undergoing bariatric procedures - 2019 update: cosponsored by American Association of
657 Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American
658 Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society
659 of Anesthesiologists. *Surgery for obesity and related diseases : official journal of the American*
660 *Society for Bariatric Surgery*. 2020;16(2):175-247.

661

Table 1. Baseline characteristics of SG participants

	All (n = 54)	Premenopausal women (n = 26)	Postmenopausal women (n = 15)	Men (n = 13)
Age, yr	46.2 ± 11.1	38.5 ± 7.3	57.9 ± 6.4 ^a	47.9 ± 9.2 ^{a,b}
Race, n (%)				
White	40 (74)	17 (65)	11 (73)	12 (92)
Black	10 (19)	6 (23)	4 (27)	
Asian	2 (4)	1 (4)		1 (8)
More than one race	2 (4)	2 (8)		
Ethnicity, n (%)				
Hispanic/Latinx	13 (24)	7 (27)	1 (7)	5 (38)
Weight, kg	126.0 ± 23.4	124.4 ± 20.3	111.9 ± 18.3	145.5 ± 22.6 ^{a,b}
BMI, kg/m ²	45.2 ± 7.5	46.8 ± 7.6	42.0 ± 6.0	45.8 ± 8.2
Percent body fat (%)	43.8 ± 4.8	45.3 ± 4.0	45.1 ± 2.2	38.5 ± 5.7 ^{a,b}
Waist circumference (cm)	119.7 ± 13.9	118.1 ± 11.1	114.2 ± 10.2	132.8 ± 18.3 ^{a,b}
Waist-hip ratio	0.86 ± 0.10	0.83 ± 0.07	0.85 ± 0.10	0.96 ± 0.10 ^{a,b}
Diabetes, n (%)	10 (19)	2 (8)	5 (33)	3 (23)
FCA, %	31.6 ± 15.0	35.6 ± 12.7	29.8 ± 17.7	22.0 ± 14.4
Serum calcium, mg/dL	9.3 ± 0.4	9.1 ± 0.3	9.4 ± 0.4 ^a	9.6 ± 0.4 ^a
Albumin, g/dL	4.1 ± 0.3	4.1 ± 0.2	4.1 ± 0.4	4.4 ± 0.4 ^{a,b}
25OHD preop visit, ng/mL	40.6 ± 13.7	38.0 ± 12.3	46.9 ± 12.7	37.8 ± 15.6
PTH, pg/mL	44.5 ± 22.5	38.9 ± 17.4	49.8 ± 28.1	49.0 ± 23.1
1,25(OH) ₂ D, pg/mL	70.0 ± 28.7	66.3 ± 28.5	73.9 ± 25.0	72.4 ± 34.5
CTx, ng/mL	0.20 (0.13,0.29)	0.15 (0.12,0.21)	0.26 (0.13,0.32)	0.31 (0.19,0.43) ^a
P1NP, ng/mL	42.4 (34.7,63.2)	36.8 (33.2,44.6)	52.3 (33.6,63.9)	64.2 (52.9,73.9) ^a
Creatinine, mg/dL	0.86 ± 0.31	0.70 ± 0.13	0.91 ± 0.37 ^a	1.10 ± 0.32 ^{a,b}
Phosphorus, mg/dL	3.6 ± 0.5	3.6 ± 0.5	3.6 ± 0.5	3.6 ± 0.5
Urinary calcium, mg/24hr	172 (80,270)	162 (91,240)	205 (57,375)	161 (95,269)
Areal BMD, g/cm ²				
Lumbar spine	1.091 ± 0.131	1.108 ± 0.120	1.087 ± 0.153	1.056 ± 0.126
Total hip	1.074 ± 0.123	1.099 ± 0.126	1.016 ± 0.125	1.104 ± 0.090
Femoral neck	0.901 ± 0.126	0.926 ± 0.133	0.846 ± 0.119	0.927 ± 0.103
Volumetric BMD, g/cm ³				
Lumbar spine	0.157 ± 0.036	0.177 ± 0.029	0.139 ± 0.027 ^a	0.133 ± 0.034 ^a

^ap<0.05 vs. premenopausal women

^bp<0.05 vs. postmenopausal women

Values are means ± SDs, median (IQR), or count (percentage).

95% reference intervals provided by the test manufacturers: PTH, 14-64 pg/mL; CTx, 0.034-1.037 ng/mL (post-menopausal women); P1NP, 27.7-127.6 ng/mL; 1,25(OH)₂D, 15.2-90.1 pg/mL.

Abbreviations: BMI, body mass index; FCA, fractional calcium absorption; 25OHD, 25-hydroxyvitamin D; PTH, intact parathyroid hormone; 1,25(OH)₂D, 1,25-dihydroxyvitamin D; CTx, collagen type 1 C-telopeptide; P1NP, procollagen 1 intact N-terminal propeptide; BMD, bone mineral density.

Table 2. Predicted percentage changes in BMD after SG

	6-month % change	12-month % change	<i>p</i>
<i>DXA</i> (n = 49)			
Total hip aBMD (g/cm ²)	-5.4 [-6.4,-4.3]	-8.0 [-9.1,-6.7]	<0.01
Femoral neck aBMD (g/cm ²)	-3.4 [-4.2,-2.5]	-6.7 [-8.3,-5.2]	<0.01
Lumbar spine aBMD (g/cm ²)	-0.7 [-1.4,-0.1]	-1.4 [-2.6,-0.3]	0.03
Distal 1/3 radius aBMD (g/cm ²)	+0.3 [-0.1,0.7]	+0.7 [-0.1,1.6]	0.11
<i>QCT</i> (n = 38)			
Lumbar spine vBMD (g/cm ³)	-1.6 [-2.9,-0.1]	-3.1 [-6.1,0.1]	0.07
<i>HRpQCT</i> (n = 37)			
Radius total vBMD (g/cm ³)	-0.4 [-1.1,0.2]	-0.8 [-2.2,0.4]	0.22
Radius trabecular vBMD (g/cm ³)	-0.9 [-1.6,-0.2]	-1.9 [-3.3,-0.5]	0.01
Radius cortical vBMD (g/cm ³)	+0.2 [-0.1,0.4]	0.4 [-0.1,0.9]	0.17
Tibia total vBMD (g/cm ³)	-1.6 [-2.2,-1.0]	-3.1 [-4.2,-1.9]	<0.01
Tibia trabecular vBMD (g/cm ³)	-1.1 [-1.7,-0.4]	-2.1 [-3.3,-0.8]	<0.01
Tibia cortical vBMD (g/cm ³)	+0.0 [-0.6,0.7]	-1.0 [-2.2,0.1]	0.20

Values are model predictions ± 95%CI

P-values, which compare to no change, were calculated with mixed effect models with repeated measures with random participant intercept and slope and fixed effect of time.

Abbreviations: DXA, dual-energy X-ray absorptiometry; aBMD, areal bone mineral density; QCT, quantitative computed tomography; vBMD, volumetric bone mineral density; HRpQCT, high-resolution peripheral quantitative computed tomography.

Table 3. Predicted percentage changes in bone microarchitecture and estimated strength after SG

HRpQCT (n = 37)	6-month % change	12-month % change	<i>p</i>
<i>Bone microarchitecture</i>			
Radius			
Trabecular area (mm ²)	-0.1 [-0.3,0.2]	-0.1 [-0.6,0.3]	0.64
Trabecular number (per mm)	-2.8 [-4.0,-1.6]	-5.6 [-8.0,-3.3]	<0.01
Trabecular separation (mm)	+3.3 [1.1,5.4]	+6.6 [2.6,11.0]	<0.01
Trabecular thickness (mm)	+1.7 [0.1,3.4]	+3.3 [0.1,6.3]	0.04
Trabecular heterogeneity (per mm)	+7.6 [0.7,14.4]	+15.2 [0.5,29.4]	0.05
Cortical thickness (mm)	-0.1 [-0.7,0.6]	-0.2 [-1.5,1.1]	0.77
Cortical porosity (%)	-0.3 [-4.0,3.7]	-0.5 [-7.7,7.4]	0.90
Cortical pore size (mm)	+1.8 [0.7,2.9]	+3.5 [1.4,5.6]	<0.01
Tibia			
Trabecular area (mm ²)	+0.3 [0.2,0.5]	+0.7 [0.4,1.0]	<0.01
Trabecular number (per mm)	-4.2 [-5.3,-2.9]	-8.3 [-10.7,-5.9]	<0.01
Trabecular separation (mm)	+5.0 [3.2,6.7]	+10.0 [6.2,13.6]	<0.01
Trabecular thickness (mm)	+3.1 [1.4,5.0]	+6.3 [2.6,9.8]	<0.01
Trabecular heterogeneity (per mm)	+6.6 [4.4,8.9]	+13.2 [8.4,17.3]	<0.01
Cortical thickness (mm)	-1.3 [-2.1,-0.6]	-2.6 [-4.2,-1.1]	<0.01
Cortical porosity (%)	+2.7 [-2.0,7.7]	+5.5 [-4.0,15.3]	0.24
Cortical pore size (mm)	+2.7 [1.7,3.7]	+5.4 [3.3,7.4]	<0.01
<i>Estimated strength</i>			
Radius			
Failure load (kN)	-0.5 [-1.2,0.3]	-0.9 [-2.4,0.5]	0.20
Stiffness (kN/mm)	-0.1 [-1.1,0.8]	-0.3 [-2.2,1.6]	0.77
Apparent modulus (kN/mm ²)	-0.3 [-1.2,0.5]	-0.7 [-2.2,1.1]	0.44
Tibia			
Failure load (kN)	-1.1 [-1.9,-0.3]	-2.3 [-3.9,-0.7]	<0.01
Stiffness (kN/mm)	-0.8 [-1.7,0.1]	-1.7 [-3.4,-0.1]	0.06
Apparent modulus (kN/mm ²)	-0.9 [-1.7,-0.1]	-1.8 [-3.5,-0.1]	0.04

Values are model prediction ± 95%CI

P-values, which compare to no change, were calculated with mixed effect models with repeated measures with random participant intercept and slope and fixed effect of time

Abbreviations: DXA, dual-energy X-ray absorptiometry; aBMD, areal bone mineral density; QCT, quantitative computed tomography; vBMD, volumetric bone mineral density; HRpQCT, high-resolution peripheral quantitative computed tomography.

Figure 1: Changes in BMD, bone microarchitecture, and estimated strength that were significantly different by sex and menopausal status. Shaded areas represent the 95% confidence intervals.




Figure 2: Changes in BMD, bone microarchitecture, and estimated strength that were significantly different by surgical procedure. Shaded areas represent the 95% confidence intervals.

